4.7 Article

Age and disability accumulation in multiple sclerosis

Journal

NEUROLOGY
Volume 77, Issue 13, Pages 1246-1252

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318230a17d

Keywords

-

Funding

  1. Italian Multiple Sclerosis Foundation (FISM) [2008/R/16]
  2. Medical Research Council [G0800679]
  3. MS Society of Canada
  4. UK MS Society
  5. Kompetenznetz Multiple Sklerose (Competence Network for Multiple Sclerosis)
  6. Federal Ministry of Education and Research (BMBF) [FKZ 01Gl0904, 01Gl0920]
  7. German Ministry for Education and Research (BMBF)
  8. ECTRIMS
  9. EU
  10. BWiMi
  11. Hertie Foundation
  12. Bayer Schering Pharma
  13. sanofi-aventis
  14. Roche
  15. UCB
  16. Medical Research Council UK
  17. UK Multiple Sclerosis Society/UK Stem Cell Foundation
  18. Italian Multiple Sclerosis Foundation (FISM)
  19. Medical Research Council [G0800679] Funding Source: researchfish
  20. MRC [G0800679] Funding Source: UKRI

Ask authors/readers for more resources

Objectives: We tested the hypothesis that age is a prognostic factor with respect to long-term accumulation of disability in multiple sclerosis (MS). Methods: Kaplan-Meier analysis and binary logistic regression models determined the effect of age at disease onset, age at onset of progression, and current age on attainment of severe disability levels (Disability Status Scale [DSS] 6-8-10) from the London, Ontario, database (n = 1,023). Results: Older age at relapsing-remitting (RR) phase onset was associated with higher risk of reaching advanced DSS scores. This was independent of disease duration and early relapse frequency but secondary to increased risk of conversion to secondary progressive (SP) MS. Onset at age 40 (odds ratio [OR] = 4.22) and at age 50 (OR = 6.04) doubled and tripled risks of developing SP, compared to age 20 (OR = 2.05). Younger age at conversion to SPMS was associated with shorter times to high DSS scores from disease onset. The progressive course, unaffected by age at RR onset, was only modestly affected by age at SP onset. Among primary progressive and RR/SP patients, median ages at attainment of DSS scores were strikingly similar: DSS = 6, 49 vs 48 years; DSS = 8, 58 vs 58 years; and DSS = 10, 78 years for both (p = NS for all comparisons). Conclusions: Development of SP is the dominant determinant of long-term prognosis, independent of disease duration and early relapse frequency. Age independently affects disability development primarily by changing probability and latency of SP onset, with little effect on the progressive course. Neurology (R) 2011; 77: 1246-1252

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available